After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline.

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...

Fact checked by Nick Blackmer It all started back in the spring of 2018 with a painful bump in my armpit. Confused, scared, ...

UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®▼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...

The following is a summary of “Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a ...

Discover a review in which diabetes was investigated in 5 studies, with only one demonstrating a correlation between the condition and higher hospital readmission rates.

Managing hidradenitis suppurativa (HS) poses an array of challenges. This chronic inflammatory skin condition causes multiple symptoms, including painful abscesses in skin folds that ooze pus and ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals ...

The following is a summary of “Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidity.,” published in the February 2025 issue ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including ...